{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:43:52Z","timestamp":1777308232000,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Eastern Finland (UEF) including Kuopio University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00228-018-2591-5","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T17:34:40Z","timestamp":1541784880000},"page":"417-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"75","author":[{"given":"Reetta","family":"Kettunen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-934X","authenticated-orcid":false,"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maija","family":"Tolppanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirpa","family":"Hartikainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjaana","family":"Koponen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"2591_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00127-016-1306-4","volume":"52","author":"B Mars","year":"2017","unstructured":"Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, Gunnell D (2017) Influences on antidepressant prescribing trends in the UK: 1995\u20132011. Soc Psychiatry Psychiatr Epidemiol 52:193\u2013200. \n                    https:\/\/doi.org\/10.1007\/s00127-016-1306-4","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2591_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.euroneuro.2014.10.004","volume":"24","author":"H Taipale","year":"2014","unstructured":"Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S (2014) High prevalence of psychotropic drug use among persons with and without Alzheimer [U+05F3] s disease in Finnish nationwide cohort. Eur Neuropsychopharmacol 24:1729\u20131737. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2014.10.004","journal-title":"Eur Neuropsychopharmacol"},{"key":"2591_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1017\/S1041610214002427","volume":"27","author":"M-L Laitinen","year":"2015","unstructured":"Laitinen M-L, L\u00f6nnroos E, Bell JS, Lavikainen P, Sulkava R, Hartikainen S (2015) Use of antidepressants among community-dwelling persons with Alzheimer\u2019s disease: a nationwide register-based study. Int Psychogeriatr 27:669\u2013672. \n                    https:\/\/doi.org\/10.1017\/S1041610214002427","journal-title":"Int Psychogeriatr"},{"key":"2591_CR4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3233\/JAD-160238","volume":"53","author":"R David","year":"2016","unstructured":"David R, Manera V, Fabre R, Pradier C, Robert P, Tifratene K (2016) Evolution of the antidepressant prescribing in Alzheimer\u2019s disease and related disorders between 2010 and 2014: results from the French National Database on Alzheimer\u2019s disease (BNA). J Alzheimers Dis 53:1365\u20131373. \n                    https:\/\/doi.org\/10.3233\/JAD-160238","journal-title":"J Alzheimers Dis"},{"key":"2591_CR5","doi-asserted-by":"publisher","first-page":"j603","DOI":"10.1136\/bmj.j603","volume":"356","author":"J Wong","year":"2017","unstructured":"Wong J, Motulsky A, Abrahamowicz M et al (2017) Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 356:j603. \n                    https:\/\/doi.org\/10.1136\/bmj.j603","journal-title":"BMJ"},{"key":"2591_CR6","first-page":"CD008191","volume":"16","author":"D Seitz","year":"2011","unstructured":"Seitz D, Adunuri N, Gill S, Al E (2011) Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 16:CD008191","journal-title":"Cochrane Database Syst Rev"},{"key":"2591_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3233\/JAD-161247","volume":"58","author":"V Orgeta","year":"2017","unstructured":"Orgeta V, Tabet N, Nilforooshan R, Howard R (2017) Efficacy of antidepressants for depression in Alzheimer\u2019s disease: systematic review and meta-analysis. J Alzheimers Dis 58:725\u2013733. \n                    https:\/\/doi.org\/10.3233\/JAD-161247","journal-title":"J Alzheimers Dis"},{"key":"2591_CR8","doi-asserted-by":"publisher","first-page":"d4551","DOI":"10.1136\/bmj.d4551","volume":"343","author":"C Coupland","year":"2011","unstructured":"Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Bmj 343:d4551. \n                    https:\/\/doi.org\/10.1136\/bmj.d4551","journal-title":"Bmj"},{"key":"2591_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000477940","volume":"86","author":"MM Maslej","year":"2017","unstructured":"Maslej MM, Bolker BM, Russell MJ, Eaton K, Durisko Z, Hollon SD, Swanson GM, Thomson Jr JA, Mulsant BH, Andrews PW (2017) The mortality and myocardial effects of antidepressants are moderated by preexisting cardiovascular disease: a meta-analysis. Psychother Psychosom 86:268\u2013282. \n                    https:\/\/doi.org\/10.1159\/000477940","journal-title":"Psychother Psychosom"},{"key":"2591_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/11594710-000000000-00000","volume":"26","author":"E Spina","year":"2012","unstructured":"Spina E, Trifir\u00f2 G, Caraci F (2012) Clinically significant drug interactions with newer antidepressants. CNS Drugs 26:39\u201367. \n                    https:\/\/doi.org\/10.2165\/11594710-000000000-00000","journal-title":"CNS Drugs"},{"key":"2591_CR11","doi-asserted-by":"publisher","unstructured":"Taipale H, Koponen M, Tanskanen A et al (2017) Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer\u2019s disease: a nationwide matched cohort study. Alzheimer\u2019s Res Ther:9. \n                    https:\/\/doi.org\/10.1186\/s13195-017-0285-3","DOI":"10.1186\/s13195-017-0285-3"},{"key":"2591_CR12","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1002\/gps.4667","volume":"32","author":"S Torvinen-Kiiskinen","year":"2017","unstructured":"Torvinen-Kiiskinen S, Tolppanen A-M, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, Taipale H (2017) Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer\u2019s disease. Int J Geriatr Psychiatry 32:e107\u2013e115. \n                    https:\/\/doi.org\/10.1002\/gps.4667","journal-title":"Int J Geriatr Psychiatry"},{"key":"2591_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, CitAD Research Group (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311:682\u2013691. \n                    https:\/\/doi.org\/10.1001\/jama.2014.93","journal-title":"JAMA"},{"key":"2591_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000491524","volume":"87","author":"GA Fava","year":"2018","unstructured":"Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J (2018) Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom 87:195\u2013203. \n                    https:\/\/doi.org\/10.1159\/000491524","journal-title":"Psychother Psychosom"},{"key":"2591_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-011-1087-3","volume":"68","author":"CY Lu","year":"2012","unstructured":"Lu CY, Roughead E (2012) New users of antidepressant medications: first episode duration and predictors of discontinuation. Eur J Clin Pharmacol 68:65\u201371. \n                    https:\/\/doi.org\/10.1007\/s00228-011-1087-3","journal-title":"Eur J Clin Pharmacol"},{"key":"2591_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/fcp.12252","volume":"31","author":"D Braunstein","year":"2017","unstructured":"Braunstein D, Hardy A, Boucherie Q, Frauger E, Blin O, Gentile G, Micallef J (2017) Antidepressant adherence patterns in older patients: use of a clustering method on a prescription database. Fundam Clin Pharmacol 31:226\u2013236. \n                    https:\/\/doi.org\/10.1111\/fcp.12252","journal-title":"Fundam Clin Pharmacol"},{"key":"2591_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00228-016-2145-7","volume":"73","author":"K Jobski","year":"2017","unstructured":"Jobski K, Schmedt N, Kollhorst B, Krappweis J, Schink T, Garbe E (2017) Characteristics and drug use patterns of older antidepressant initiators in Germany. Eur J Clin Pharmacol 73:105\u2013113. \n                    https:\/\/doi.org\/10.1007\/s00228-016-2145-7","journal-title":"Eur J Clin Pharmacol"},{"key":"2591_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5414\/CP202572","volume":"54","author":"A Booker","year":"2016","unstructured":"Booker A, Bohlken J, Rapp MA, Kostev K (2016) Persistence with antidepressant drugs in patients with dementia: a retrospective database analysis. Int J Clin Pharmacol Ther 54:323\u2013329. \n                    https:\/\/doi.org\/10.5414\/CP202572","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2591_CR19","doi-asserted-by":"publisher","first-page":"e012100","DOI":"10.1136\/bmjopen-2016-012100","volume":"6","author":"A-M Tolppanen","year":"2016","unstructured":"Tolppanen A-M, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, Hartikainen S (2016) Cohort profile: the Finnish medication and Alzheimer\u2019s disease (MEDALZ) study. BMJ Open 6:e012100. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2016-012100","journal-title":"BMJ Open"},{"key":"2591_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"2591_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","volume":"15","author":"A Tanskanen","year":"2015","unstructured":"Tanskanen A, Taipale H, Koponen M, Tolppanen AM, Hartikainen S, Ahonen R, Tiihonen J (2015) From prescription drug purchases to drug use periods \u2013 a second generation method (PRE2DUP). BMC Med Inform Decis Mak 15:21. \n                    https:\/\/doi.org\/10.1186\/s12911-015-0140-z","journal-title":"BMC Med Inform Decis Mak"},{"key":"2591_CR22","first-page":"547","volume":"67","author":"AZ Ables","year":"2003","unstructured":"Ables AZ, Baughman OL (2003) Antidepressants: update on new agents and indications. Am Fam Physician 67:547\u2013554","journal-title":"Am Fam Physician"},{"key":"2591_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanp\u00e4\u00e4 M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14:162\u2013173. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0","journal-title":"Lancet Neurol"},{"key":"2591_CR24","unstructured":"Finnish Medical Society Duodecim. Memory disorders: Current Care Guidelines (in Finnish with English abstract). The Finnish Medical Society Duodecim. Available at: \n                    www.kaypahoito.fi\n                    \n                   Accessed 29 March 2018"},{"key":"2591_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1517\/17425255.2015.1021684","volume":"11","author":"J Sultana","year":"2015","unstructured":"Sultana J, Spina E, Trifir\u00f2 G (2015) Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol 11:883\u2013892. \n                    https:\/\/doi.org\/10.1517\/17425255.2015.1021684","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2591_CR26","doi-asserted-by":"publisher","unstructured":"Seppala LJ, Wermelink AM, de Vries M et al (2018) Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics. J Am Med Dir Assoc. \n                    https:\/\/doi.org\/10.1016\/j.jamda.2017.12.013","DOI":"10.1016\/j.jamda.2017.12.013"},{"issue":"suppl","key":"2591_CR27","first-page":"5","volume":"164","author":"P Rabins","year":"2007","unstructured":"APA Work Group on Alzheimer's Disease and other Dementias, Rabins P, Blacker D et al (2007) American psychiatric association practice guideline for the treatment of patients with Alzheimer\u2019s disease and other dementias. Second edition. Am J Psychiatry 164(suppl):5\u201356","journal-title":"Am J Psychiatry"},{"key":"2591_CR28","doi-asserted-by":"crossref","unstructured":"Alam A, Voronovich Z, Carley JA (2013) A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS disord 15(5):24511451","DOI":"10.4088\/PCC.13r01525"},{"key":"2591_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/psyg.12191","volume":"17","author":"FM Scoralick","year":"2017","unstructured":"Scoralick FM, Louzada LL, Quintas JL, Naves JOS, Camargos EF, N\u00f3brega OT (2017) Mirtazapine does not improve sleep disorders in Alzheimer\u2019s disease: results from a double-blind, placebo-controlled pilot study. Psychogeriatrics 17:89\u201396. \n                    https:\/\/doi.org\/10.1111\/psyg.12191","journal-title":"Psychogeriatrics"},{"key":"2591_CR30","unstructured":"Duodecim FMS (2016) Current care: sleep disorders. \n                    http:\/\/www.kaypahoito.fi\n                    \n                  . Accessed 13 May 2018"},{"key":"2591_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.12740\/PP\/64477","volume":"50","author":"UW Preuss","year":"2016","unstructured":"Preuss UW, Wong J, Koller G (2016) Treatment of behavioral and psychological symptoms of dementia: a systematic review. Psychiatr Pol 50:679\u2013715. \n                    https:\/\/doi.org\/10.12740\/PP\/64477","journal-title":"Psychiatr Pol"},{"key":"2591_CR32","doi-asserted-by":"publisher","unstructured":"Martinez C, Jones RW, Rietbrock S (2013) Trends in the prevalence of antipsychotic drug use among patients with Alzheimer\u2019s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open 3. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2012-002080","DOI":"10.1136\/bmjopen-2012-002080"},{"key":"2591_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000158226","volume":"31","author":"J-S Vidal","year":"2008","unstructured":"Vidal J-S, Lacombe J-M, Dartigues J-F et al (2008) Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology 31:193\u2013200. \n                    https:\/\/doi.org\/10.1159\/000158226","journal-title":"Neuroepidemiology"},{"key":"2591_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/gps.1949","volume":"23","author":"S Gauthier","year":"2008","unstructured":"Gauthier S, Loft H, Cummings J (2008) Improvement in behavioral symptoms in patients with moderate to severe Alzheimer\u2019s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 23:537\u2013545. \n                    https:\/\/doi.org\/10.1002\/gps","journal-title":"Int J Geriatr Psychiatry"},{"key":"2591_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/jcpt.12469","volume":"42","author":"M Amidfar","year":"2017","unstructured":"Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, Zarrindast MR, Mohammadinejad P, Zeinoddini A, Akhondzadeh S (2017) Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. J Clin Pharm Ther 42:44\u201350. \n                    https:\/\/doi.org\/10.1111\/jcpt.12469","journal-title":"J Clin Pharm Ther"},{"key":"2591_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/CLEP.S116160","volume":"8","author":"H Taipale","year":"2016","unstructured":"Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S (2016) Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. Clin Epidemiol 8:363\u2013371. \n                    https:\/\/doi.org\/10.2147\/CLEP.S116160","journal-title":"Clin Epidemiol"},{"key":"2591_CR37","doi-asserted-by":"publisher","first-page":"e0184070","DOI":"10.1371\/journal.pone.0184070","volume":"12","author":"A Tanskanen","year":"2017","unstructured":"Tanskanen A, Taipale H, Koponen M, Tolppanen AM, Hartikainen S, Ahonen R, Tiihonen J (2017) Drug exposure in register-based research -an expert-opinion based evaluation of methods. PLoS One 12:e0184070","journal-title":"PLoS One"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2591-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2591-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2591-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T19:11:05Z","timestamp":1573240265000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2591-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2591"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2591-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"8 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to Finnish legislation, no ethics committee approval is required as only register-based data was used and participants were not contacted in any way.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HT, JT, and AT have participated in research projects funded by Janssen and Eli Lilly with grants paid to the institution where they were employed. AT is a member of Janssen advisory board. JT has served as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline; lecture fees from Janssen-Cilag, Bristol-Myers Squibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, AstraZeneca, and Novartis; and grant from Stanley Foundation. JT is a member of advisory board in AstraZeneca, Janssen-Cilag, and Otsuka. MK has received personal research grant from Oy H. Lundbeck Ab foundation outside the submitted work. Other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}